Expanded A.I. and machine learning capabilities will accelerate Mydecine’s broader research and development efforts DENVER, June 16, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for…


Previous articleBright Minds Biosciences Announces Application to List on Nasdaq
Next articlePsilocybin for Depression: A Q&A between Robin Carhart-Harris & a Psilocybin Study Participant